High BP Tablets in India: Drug Classes, Names and Pricing
High BP tablets in India by drug class: ACE inhibitors, ARBs, CCBs, diuretics and beta blockers, with NPPA price status and Jan Aushadhi costs.
This guide to high BP tablets India covers what each drug class does, which molecules dominate Indian prescribing, where government price control applies, and what a hospital pharmacy needs to get right when stocking this category long-term.
What are ACE inhibitors and which ones are used in India?
ACE inhibitors block the enzyme that converts angiotensin I to angiotensin II, relaxing blood vessels and lowering pressure. Enalapril and ramipril are the two names seen most in Indian prescribing, both listed in India's National List of Essential Medicines NLEM 2022.
Ramipril tends to appear more often in post-cardiac-event prescribing because of its additional evidence base in reducing cardiovascular events, while enalapril is the older, more widely genericised molecule. Both classes carry a well-documented dry cough as a class-level side effect, which is precisely why ARBs exist as an alternative rather than a competing option — a patient who develops the cough on one is routinely moved to the other class, not to a higher dose of the same one.
Neither enalapril nor ramipril is a household name in India the way telmisartan is; ARBs have largely displaced ACE inhibitors as the first-choice renin-angiotensin blocker in general practice, and ACE inhibitors now show up more in patients already stabilised on them for years than in fresh prescriptions.
What are ARBs and why is telmisartan so dominant in Indian prescribing?
Angiotensin receptor blockers (ARBs) block the angiotensin II receptor directly rather than the enzyme upstream of it, avoiding the cough associated with ACE inhibitors. Telmisartan is the most widely prescribed ARB in India, followed by losartan, both listed as essential medicines.
India's hypertension control programme, the India Hypertension Control Initiative, adopted state-level drug protocols in which telmisartan sits explicitly as the second-step drug after amlodipine, based on a WHO HEARTS-adapted regimen using amlodipine 5 mg plus telmisartan 40 mg as a single-pill combination protocol. That protocol placement, not marketing, is why telmisartan shows up on so many prescription pads.
Losartan remains in wide use too, particularly in patients with gout history since it has a mild uricosuric effect other ARBs lack — a detail that matters more to a treating physician's molecule choice than most patients ever realise.
What are calcium channel blockers and why is amlodipine the first-line default?
Calcium channel blockers relax vascular smooth muscle by blocking calcium entry into cells. Amlodipine is the dominant molecule in this class across India and functions as the first-step drug in the national hypertension control protocol, ahead of both ARBs and diuretics.
Its dominance is partly pharmacokinetic: amlodipine has a long half-life that tolerates a missed dose better than shorter-acting antihypertensives, which matters directly for a chronic-adherence condition. It is also the cheapest of the major classes at scale, a fact borne out in published Indian pricing data covered below.
Amlodipine's most common class-level side effect is ankle swelling (peripheral oedema), dose-related and one of the more frequent reasons a treating physician switches a patient's regimen rather than simply increasing the amlodipine dose further.
What diuretics are used for high BP in India — chlorthalidone versus hydrochlorothiazide?
Thiazide-type diuretics lower blood pressure by reducing sodium reabsorption in the kidney, and chlorthalidone and hydrochlorothiazide are the two names used in Indian antihypertensive prescribing. Chlorthalidone has a longer half-life and is the diuretic named explicitly in India's national hypertension protocol as the third-step drug.
Hydrochlorothiazide remains common too, particularly in older fixed-dose combination products already established in the market. A 2022 published Indian pricing study measured chlorthalidone 12.5 mg at a private-sector median around ₹5.79 per tablet, against ₹1.3 through Jan Aushadhi and ₹0.7 in public-sector procurement source.
Both drugs carry the same class caution around electrolyte monitoring, particularly potassium and sodium, in patients on long-term therapy or co-prescribed with other agents that affect renal handling of these electrolytes.
What beta blockers are prescribed for high BP, and how has their role changed?
Beta blockers reduce heart rate and cardiac output by blocking beta-adrenergic receptors, and metoprolol is the name most encountered in Indian antihypertensive prescribing, usually as its succinate extended-release salt. Global and Indian guidance no longer places beta blockers as a first-line choice for uncomplicated hypertension, reserving them instead for patients with a compelling co-indication.
That co-indication is usually coronary artery disease, heart failure with reduced ejection fraction, or a rate-control need alongside atrial fibrillation — situations where a beta blocker earns its place for reasons beyond blood pressure alone. A patient without one of those conditions is far more likely to be started on amlodipine, telmisartan or an ACE inhibitor first.
Metoprolol also appears frequently in fixed-dose triple-combination products with telmisartan and a calcium channel blocker such as cilnidipine, reflecting how often Indian prescribing stacks classes once single-drug control fails rather than pushing one molecule to its ceiling dose.
Are high BP tablets under NPPA price control in India?
Some antihypertensive formulations sit under the Drug Price Control Order (DPCO) 2013 and carry an NPPA ceiling price; many combination products do not, and pricing on those follows ordinary market competition. NPPA had fixed ceiling prices on 928 scheduled formulations as of March 2025, revised annually against the wholesale price index NPPA notification.
A November 2025 NPPA retail price fixation covered several telmisartan combination products specifically: telmisartan 40 mg with amlodipine 5 mg at ₹7.14 per tablet, telmisartan 80 mg with amlodipine 5 mg at ₹9.82, and a triple combination of telmisartan, cilnidipine and metoprolol succinate at ₹11.39 to ₹14.35 per tablet depending on strength, exclusive of GST source.
A ceiling price fixes an upper bound on one named manufacturer's formulation, strength and pack size — it does not standardise every telmisartan or amlodipine product on the market. That is why brand-to-brand price differences persist within this category even where price control technically applies.
What does Jan Aushadhi generic pricing look like for high BP tablets?
Jan Aushadhi generic pricing runs at a small fraction of typical branded retail cost for the same molecule and strength. A 2022 published pricing study found amlodipine 5 mg at ₹0.5 per tablet through the Pradhan Mantri Bhartiya Janaushadhi Pariyojana scheme, against a private-sector median of ₹2.8, and telmisartan 40 mg at ₹1.1 against a private median of ₹7.19 PMC study.
The same study modelled full annual per-patient antihypertensive cost across three market segments using WHO HEARTS-style treatment protocols: private-sector pricing ran $33.88 to $68.83 a year, Jan Aushadhi pricing brought that down to $5.78 to $9.89, and public-sector procurement reached $2.05 to $3.98 Journal of Human Hypertension, 2022. That is roughly an 80% cost reduction moving from branded retail to the generic scheme, for identical molecules at identical strengths.
Jan Aushadhi outlets are listed on the PMBJP portal, and a hospital's own in-house pharmacy can stock generic-equivalent versions of these same molecules at comparable margins without sending the patient elsewhere for a cheaper strip.
How does a hospital pharmacy decide which antihypertensive brands to stock?
Stocking high BP tablets India-wide well means naming a default brand or generic per molecule, since hypertension needs the same tablet every month for years, not a short course. Switching brands mid-therapy, even within the same molecule and strength, unsettles some patients' control and their confidence in the prescription.
Running out of the specific amlodipine or telmisartan brand a patient has been stabilised on, and substituting whatever is on the shelf that week, is a common and avoidable failure point. It forces either an outside-chemist trip at an unpredictable price or an unplanned brand switch the treating physician never intended. A managed hospital pharmacy that maintains consistent in-house stock of the antihypertensive brands its own doctors actually prescribe keeps that continuity intact, and the pricing discipline behind branded versus generic margins determines whether that stocking decision is sustainable at scale rather than a one-off favour to a regular patient.
Sources
- 1Financial implications of protocol-based hypertension treatment: an insight into medication costs in public and private health sectors in India — Journal of Human Hypertension, 2022
- 2Financial implications of protocol-based hypertension treatment (full text with pricing table) — PMC, National Institutes of Health
- 3National Pharmaceutical Pricing Authority fixes ceiling prices of 928 scheduled formulations as on 25.3.2025 — Press Information Bureau, Government of India
- 4NPPA fixes retail price of 28 drugs, ceiling price of six formulations — Business Standard, reporting NPPA's November 2025 notification
- 5Dr Mansukh Mandaviya launches National List of Essential Medicines (NLEM) 2022 — Press Information Bureau, Government of India
- 6Pradhan Mantri Bhartiya Janaushadhi Pariyojana — Department of Pharmaceuticals, Government of India
- 7National Pharmaceutical Pricing Authority — ceiling prices of scheduled formulations under DPCO 2013
This article is for informational purposes and is not a substitute for professional medical advice. Consult a treating physician before starting, stopping or switching blood pressure medication.
FAQ
Frequently asked questions
Amlodipine is the most widely used first-step antihypertensive in India's national hypertension control protocol, with telmisartan the dominant second-step ARB. Both are listed on the National List of Essential Medicines and available at low cost through Jan Aushadhi outlets nationwide.
Both are ARBs with a similar mechanism; telmisartan has a longer half-life and dominates Indian protocol-based prescribing, while losartan carries a mild uricosuric effect useful in patients with gout history. The specific choice depends on individual patient factors a treating physician assesses directly.
Pricing varies enormously by brand. A 2022 published study found branded amlodipine running about 5–6 times the Jan Aushadhi generic price and branded telmisartan roughly 6–7 times its generic equivalent, for the identical molecule and strength.
Single-drug therapy often fails to control blood pressure adequately at tolerable doses, so protocols step up to a second drug (commonly an ARB) and then a third (a diuretic) rather than pushing one molecule to its ceiling dose and its ceiling side effects.
Switching between manufacturer brands of the same molecule and strength is common practice, but hypertension control depends on consistent daily adherence, and unplanned switches can unsettle some patients' readings or confidence. A treating physician should be informed of any brand change.
Current guidance places amlodipine, ARBs and ACE inhibitors ahead of beta blockers as first-line options for uncomplicated hypertension; beta blockers like metoprolol are reserved for patients with an additional cardiac indication such as coronary artery disease or heart failure.
Dr. Priya MenonMBBS, MD (General Medicine)
Consultant Physician (Internal Medicine)
Dr. Priya Menon is a consultant physician in internal medicine, writing on drug classes, side-effect profiles, and evidence-based clinical use for hospital and prescriber audiences.